Vol 28, No 3 (2021)
Editorial
Published online: 2021-05-25
Measuring the QT interval on the go
Abstract
Not available
References
- Li G, Saguner AM, An J, et al. Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality. Cardiol J. 2020; 27(5): 616–624.
- Abellas-Sequeiros M, Lozano-Granero C, Garcia-Sebastian C, et al. Monitoring of QTc interval in patients with COVID-19. First experience with a portable ECG-recording device. Cardiol J. 2021 [Epub ahead of print].
- Horby P, Mafham M, Linsell L, et al. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020; 383(21): 2030–2040.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N Engl J Med. 2020; 383(21): 2041–2052.
- Mitjà O, Corbacho-Monné M, Ubals M, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of COVID-19. N Engl J Med. 2021; 384(5): 417–427.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020; 382(19): 1787–1799.
- Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012; 3(5): 241–253.
